Home › Compare › NHWK vs SCHD

NHWK vs SCHD: Dividend Comparison 2026

NHWK yields 483.68% · SCHD yields 3.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NHWK wins by $47545.48M in total portfolio value
10 years
NHWK
NHWK
● Live price
483.68%
Share price
$0.41
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47545.50M
Annual income
$33,799,115,558.44
Full NHWK calculator →
SCHD
Schwab U.S. Dividend Equity ETF
● Live price
3.44%
Share price
$30.68
Annual div
$1.06
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.0K
Annual income
$422.61
Full SCHD calculator →

Portfolio growth — NHWK vs SCHD

📍 NHWK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNHWKSCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NHWK + SCHD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
NHWK pays
SCHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NHWK
Annual income on $10K today (after 15% tax)
$41,112.45/yr
After 10yr DRIP, annual income (after tax)
$28,729,248,224.67/yr
SCHD
Annual income on $10K today (after 15% tax)
$292.49/yr
After 10yr DRIP, annual income (after tax)
$359.22/yr
At 15% tax rate, NHWK beats the other by $28,729,247,865.46/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NHWK + SCHD for your $10,000?

NHWK: 50%SCHD: 50%
100% SCHD50/50100% NHWK
Portfolio after 10yr
$23772.77M
Annual income
$16,899,557,990.52/yr
Blended yield
71.09%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NHWK right now

NHWK
Analyst Ratings
1
Buy
2
Hold
Consensus: Hold
Altman Z
-23.2
Piotroski
2/9
SCHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NHWK buys
0
SCHD buys
0
No recent congressional trades found for NHWK or SCHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNHWKSCHD
Forward yield483.68% ✓3.44%
Annual dividend / share$2.00 ✓$1.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$47545.50M ✓$29.0K
Annual income after 10y$33,799,115,558.44 ✓$422.61
Total dividends collected$46341.12M ✓$3.9K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: NHWK vs SCHD ($10,000, DRIP)

YearNHWK PortfolioNHWK Income/yrSCHD PortfolioSCHD Income/yrGap
1← crossover$59,068$48,367.59$11,224$344.10+$47.8K → NHWK
2$330,208$267,005.36$12,567$354.98+$317.6K → NHWK
3$1,748,322$1,394,999.67$14,038$365.30+$1.73M → NHWK
4$8,773,493$6,902,788.17$15,648$375.06+$8.76M → NHWK
5$41,761,303$32,373,666.26$17,410$384.27+$41.74M → NHWK
6$188,700,228$144,015,633.00$19,335$392.95+$188.68M → NHWK
7$810,078,188$608,168,944.52$21,437$401.10+$810.06M → NHWK
8$3,306,812,597$2,440,028,935.93$23,733$408.75+$3306.79M → NHWK
9$12,847,092,568$9,308,803,088.84$26,237$415.91+$12847.07M → NHWK
10$47,545,504,606$33,799,115,558.44$28,968$422.61+$47545.48M → NHWK

NHWK vs SCHD: Complete Analysis 2026

NHWK — Stock

NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. The company has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is headquartered in Morrisville, North Carolina.

Full NHWK Calculator →

SCHD — ETF

The fund’s goal is to track as closely as possible, before fees and expenses, the total return of the Dow Jones U.S. Dividend 100 Index.

Full SCHD Calculator →
📬

Get this NHWK vs SCHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NHWK vs JEPINHWK vs ONHWK vs KONHWK vs MAINNHWK vs VYMNHWK vs DGRONHWK vs VIGNHWK vs HDV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.